At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed non-small cell lung cancer (NSCLC)
- ✓Completely resected stage I-IIIB disease with surgery >4 weeks but ≤4 years ago, OR unresectable stage IIIA/IIIB disease previously treated with definitive radiotherapy or chemotherapy >6 weeks ago
- ✓Clinically stable disease on imaging within 6 weeks with no progressive disease
- ✓No malignant pleural or pericardial effusions
- ✕No known HIV positivity or other immunosuppressive disorders
- ✕No significant cardiac disease including NYHA class III-IV heart failure, hemodynamically significant valvular disease, MI within 6 months, active angina, uncontrolled arrhythmia, stroke within 1 year, or cerebrovascular disease
- ✕No known history of infectious hepatitis
- ✕No concurrent chemotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating autologous dendritic cell cancer vaccine for Lung Cancer. Completed, enrolled 32 participants across 1 site.
Detailed Summary
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Study Details
Timeline
Interventions
Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.